Keryx to hold conference call

    Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2003 
            Financial Results on Thursday, May 15 at 9:30 a.m. EDT 
 
    NEW YORK, May 8 -- Keryx Biopharmaceuticals, Inc. 
will hold a conference call at 9:30 a.m. EDT on Thursday, May 15, 2003.  
Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will 
host the call.  Mr. Weiss will discuss the Company's first quarter results for 
2003, as well as provide an overview and update on the Company's projects.  
Keryx expects to announce its financial results for this period in a press 
release to be issued before the opening of the market on Wednesday, May 14, 
2003.   
    In order to participate in the conference call, please call 1-877-323-6160 
(U.S.) ID Code: Keryx, 1-888-752-4880 (Canada), 1-800-270-077 (Israel),  
0-800-085-7917 (UK), 0-800-918-447 (France), 0-800-562-074 (Switzerland), and 
0-800-1813-496 (Germany).   
    The press release announcing our financial results can be accessed by 
visiting the Company's website at www.keryx.com on Wednesday, May 14, 2003.  
The conference call will also will be available for replay at www.keryx.com 
for a period of 15 days after the call.  
 
    ABOUT KERYX BIOPHARMACEUTICALS, INC. 
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceuticals company engaged in the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of 
serious, life-threatening diseases, including diabetes and cancer.  Keryx is 
developing KRX-101 (sulodexide), a novel treatment for diabetic nephropathy, 
for which it is in the process of planning its U.S.-based clinical program.  
Keryx is also seeking in-licensing opportunities of additional clinical-stage 
drug candidates.  In addition, Keryx is seeking partners for its novel 
KinAceTM drug discovery technology, which allows for rapid and rational 
development of drug candidates that target a vast range of protein kinases, 
and its associated product candidates.   
 
    Cautionary Statement 
    Statements contained or referenced in this news release that are not 
historical facts, may be forward-looking statements, as the term is defined in 
the Private Litigation Reform Act of 1995.  In some cases, you can identify 
forward-looking statements by terminology such as "anticipate," "estimate," 
"expect," "project," "hope," "should," "intend," "plan," "believe," 
"scheduled," will," and other words and terms of similar meaning in connection 
with any discussion of future operating or financial performance.  Important 
factors may cause Keryx's actual results to differ materially, including: 
adverse results in its drug discovery and clinical development processes; 
failure to obtain patent protection for its discoveries; commercial 
limitations imposed by patents owned or controlled by third parties; 
difficulties or delays in obtaining regulatory approvals to market products 
resulting from its development efforts; and the requirement for substantial 
funding to conduct research and development, and to expand commercialization 
activities.  Important factors that might cause or contribute to such a 
discrepancy include, but are not limited to, the risks discussed under the 
heading "Risk Factors" in our Annual Report or Form 10-K, which has been filed 
with the Securities and Exchange Commission, as well as other filings we 
periodically make with the Commission.  Any forward-looking statements set 
forth in this news release speak only as of the date of this news release. 
Keryx does not intend to update any of these forward-looking statements to 
reflect events or circumstances that occur after the date hereof.  This press 
release and prior releases are available at www.keryx.com.  The information in 
Keryx's website is not incorporated by reference into this press release and 
is included as an inactive textual reference only. 
 
     KERYX CONTACT:  
     Ron Bentsur               
     Director of Investor Relations      
     Keryx Biopharmaceuticals, Inc.           
     Tel: [phone]           
     E-mail: [e-mail]          
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             05/08/2003 
    /CONTACT:  Ron Bentsur, Director of Investor Relations, Keryx 
Biopharmaceuticals, Inc., [phone] or [e-mail]/ 
    /Web site:  http://www.keryx.com/ 
    (KERX) 
 
-END-
NNNN



END